Surrozen, Inc./De (SRZN) Stock Price & Analysis
Surrozen, Inc./De (SRZN) fell 6.76% to USD 19.73 as of July 25, 2026 at 06:13 UTC, according to Nexqual real-time market data.
SRZN last closed at USD 21.16; the session ranged USD 19.63–21.39 on volume of 178,349 shares. Market capitalization is $229.07M, with a 52-week range of USD 8.7–35 (NCM). Source: Nexqual, July 25, 2026 at 06:13 UTC.
Key Statistics (as of July 25, 2026 at 06:13 UTC)
| Price | USD 19.73 |
|---|---|
| Change | ▼ 6.76% (down) |
| Previous Close | USD 21.16 |
| Open | USD 21.25 |
| Day Range | USD 19.63 – 21.39 |
| 52-Week Range | USD 8.7 – 35 |
| Volume | 178,349 shares |
| Market Cap | $229.07M |
| Exchange | NCM |
Technical Analysis (SRZN)
Nexqual's technical model rates SRZN "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.63 (neutral) |
| vs SMA50 | Below (USD 24.14) |
| MACD | -0.98 (negative) |
Analyst Ratings (SRZN)
Wall Street analysts rate SRZN "Strong Buy" based on 4 analysts, with a mean price target of USD 42.5 (range USD 40–44), per Nexqual as of July 25, 2026 at 06:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 42.5 |
| High Target | USD 44 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (SRZN)
| EPS Estimate | USD -1.26 |
|---|---|
| Revenue Estimate | $869,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -4.63 vs est -0.72 ▼ miss |
| 2025-12-31 | USD -9.62 vs est -1.24 ▼ miss |
| 2025-09-30 | USD -3.6 vs est -1.17 ▼ miss |
| 2025-06-30 | USD -1.14 vs est -1.23 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:13 UTC.
Financials & Fundamentals (SRZN)
| Total Revenue | $7.49M |
|---|---|
| Revenue Growth (YoY) | +408.60% |
| Gross Margin | +0.00% |
| Operating Margin | -209.12% |
| Profit Margin | +0.00% |
| Current Ratio | 11.91 |
| Total Cash | $106.91M |
| Total Debt | $6.78M |
| Free Cash Flow | $-26.11M |
Source: Nexqual, July 25, 2026 at 06:13 UTC.
Financial Health Score (SRZN)
Nexqual rates Surrozen, Inc./De's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:13 UTC.
| Growth | Critical — Revenue -67% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $107M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$26M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SRZN)
| Insider Ownership | +3.18% |
|---|---|
| Institutional Ownership | +102.85% |
| Shares Outstanding | 11.61M |
| Float | 5.09M |
| Short % of Float | +15.21% |
Source: Nexqual, July 25, 2026 at 06:13 UTC.
Leadership (SRZN)
Surrozen, Inc./De is led by Craig C. Parker (age 63), CEO, President & Director, per Nexqual as of July 25, 2026 at 06:13 UTC.
| CEO, President & Director | Craig C. Parker (age 63) |
|---|---|
| COO & Corporate Secretary | Charles Williams (age 45) |
| Executive Vice President of Research | Yang Li (age 56) |
| Chief Financial Officer | Andrew Maleki (age 35) |
| Senior Vice President of Development Operations | Michael Lauw M.S.W. |
Major Backers & Investors (SRZN)
Notable institutional backers of Surrozen, Inc./De include Column Group LLC, TCG Crossover Management, LLC, Boxer Capital Management, LLC, according to Nexqual as of July 25, 2026 at 06:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Column Group LLC | 16.51% |
| TCG Crossover Management, LLC | 12.69% |
| Boxer Capital Management, LLC | 6.6% |
| Millennium Management | 6.3% |
| Venrock Adviser, LLC | 5.45% |
| Stempoint Capital LP | 4.53% |
| Spruce Street Capital LP | 3.72% |
| Braidwell LP | 3.41% |
Source: Nexqual, July 25, 2026 at 06:13 UTC.
From Surrozen, Inc./De's Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Technology Our proprietary platform, SWAPs, enables us to potently and selectively modulate Wnt signaling through the generation of Wnt mimetics.
- Vabysmo is one of the market-leading products and generated over $5 billion in global revenue in 2025.
- Branded anti-VEGF therapies for the treatment of retinal diseases, including wet AMD and DME, cumulatively generated over $13 billion in global revenue in 2025.
- The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF therapies, including monotherapies and dual-pathway agents targeting VEGF and angiopoietin-2, or Ang-2.
Partnerships
- We have partnered with key thought leaders in the field, including those on our Scientific Advisory Board, and have developed significant expertise in various areas of biology relevant to the Wnt signaling pathway.
- Collaboration and License Arrangements Collaboration and License Agreement with Boehringer Ingelheim International GmbH In October 2022, we executed the CLA with Boehringer Ingelheim to research, develop and commercialize Fzd4 bi-specific antibodies designed using our SWAP technology, including SZN-413.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | USD 28.29 | ▼ 1.29% |
| JSPR | Jasper Therapeutics, Inc. | USD 0.69 | ▼ 7.6% |
| CMRA | Comera Life Sciences Holdings, | USD 0 | ▲ 0% |
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
| TIL | Instil Bio, Inc. | USD 7.13 | ▼ 1.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:13 UTC. This page is informational and not investment advice.